Renal Failure Chronic Requiring Dialysis

2

Review clinical trials related to Renal Failure Chronic Requiring Dialysis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Bisacodyl Oral for Lowering Dysfunction (of Tenckhoff Catheter)

Doctors need to insert catheter for patients who are going to have peritoneal dialysis. These peritoneal catheters can be obstructed or blocked afterward. The chance of not having smooth flow can be up to 12 and 31%. So far, constipation is one of the proposed reasons. Therefore, the study is aimed to investigate whether the preventive use of laxative before the surgery can help better improve the function of the catheter and hence better flow.

Participants needed: 398
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Chinese University of Hong KongUpdated: Jan 21, 2026Locations: 6
Eligibility criteria

aged 18 or older and need of peritoneal dialysis [+1]

known contraindication to peritoneal dialysis [+3]

Status: Recruiting

Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (\> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression at 6 months. The main question this study aims to answer is: Does maintaining long-term immunosuppression in patients with a late renal graft failure (\> 3 months) safely reduce the risk of HLA sensitization? To answer this question, patients will be assigned to a control arm or investigational arm: * Patients assigned to the control arm will receive standard treatment, in which immunosuppressant treatment is withdrawn after 6 months. * Patients assigned to the investigatonal arm will continue immunosuppressant treatment at low doses for 2 years. Patients recruited in this clinical trial will be followed for up to 2 years. During this time, patients will visit the clinic every 3 months for checkups and tests.

Participants needed: 202
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Hospital Universitari Vall d'Hebron Research InstituteUpdated: Nov 6, 2024Locations: 1
Eligibility criteria

Patient must be able to understand and provide written informed consent [+6]

Patients who have received another solid organ transplantation (liver, lung, hea... [+6]